%0 Journal Article
%T Eurythmy therapy in chronic disease: a four-year prospective cohort study
%A Harald J Hamre
%A Claudia M Witt
%A Anja Glockmann
%A Renatus Ziegler
%A Stefan N Willich
%A Helmut Kiene
%J BMC Public Health
%D 2007
%I BioMed Central
%R 10.1186/1471-2458-7-61
%X In conjunction with a health benefit program, 419 outpatients from 94 medical practices in Germany, referred to 118 eurythmy therapists, participated in a prospective cohort study. Main outcomes were disease severity (Disease and Symptom Scores, physicians' and patients' assessment on numerical rating scales 0每10) and quality of life (adults: SF-36, children aged 8每16: KINDL, children 1每7: KITA). Disease Score was documented after 0, 6 and 12 months, other outcomes after 0, 3, 6, 12, 18, 24, and (SF-36 and Symptom Score) 48 months.Most common indications were mental disorders (31.7% of patients; primarily depression, fatigue, and childhood emotional disorder) and musculoskeletal diseases (23.4%). Median disease duration at baseline was 3.0 years (interquartile range 1.0每8.5). Median number of eurythmy therapy sessions was 12 (interquartile range 10每19), median therapy duration was 119 days (84每188).All outcomes improved significantly between baseline and all subsequent follow-ups (exceptions: KITA Psychosoma in first three months and KINDL). Improvements from baseline to 12 months were: Disease Score from mean (standard deviation) 6.65 (1.81) to 3.19 (2.27) (p < 0.001), Symptom Score from 5.95 (1.75) to 3.49 (2.12) (p < 0.001), SF-36 Physical Component Summary from 43.13 (10.25) to 47.10 (9.78) (p < 0.001), SF-36 Mental Component Summary from 38.31 (11.67) to 45.01 (11.76) (p < 0.001), KITA Psychosoma from 69.53 (15.45) to 77.21 (13.60) (p = 0.001), and KITA Daily Life from 59.23 (21.78) to 68.14 (18.52) (p = 0.001). All these improvements were maintained until the last follow-up. Improvements were similar in patients not using diagnosis-related adjunctive therapies within the first six study months.Adverse reactions to eurythmy therapy occurred in 3.1% (13/419) of patients. No patient stopped eurythmy therapy due to adverse reactions.Patients practising eurythmy therapy exercises had long-term improvement of chronic disease symptoms and quality of life. Although th
%U http://www.biomedcentral.com/1471-2458/7/61